HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dean Rudge

Under the guidance of editor Aidan Fry and deputy editor David Wallace, Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Advertisement
Set Alert for Articles By Dean Rudge

Latest From Dean Rudge

Industry Veteran Haggar To Lead Private Equity-Backed Zentiva From Next Month

Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.

Appointments Europe

Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs

With an eye on moving to market its broad pipeline of innovative brands, Pfizer has cut development of five early-stage biosimilar assets, in a decision that will affect 150 staff. The move is not reflective of Pfizer's overall commitment to biosimilars, the US-based company maintains.

Strategy Biosimilars

Amneal Eyes Generic Injectables Deals, While Competition Bites Sooner Than Anticipated

A strengthened cash position has provided Amneal the chance to seek inorganic opportunities to bolster its growing presence in injectables. The US-based, US-centric company is looking to grow its operations, having been surprised in recent weeks by generic competition to its most lucrative generic assets.

Strategy Pricing Debate

Teva Shells Out US$135m To Settle State Fraud Case

Teva has finalized a US$135 million payment to the US state of Illinois, the result of a protracted lawsuit alleging the Israeli firm caused Medicaid to overpay for prescription drugs due to inflated average wholesale prices.

Legal Issues Medicaid

Coherus BioSciences Outlines ‘Very Different Approach’ And Raises Another US$75m To Launch Udenyca

Just days after it began selling the second biosimilar pegfilgrastim product in the US, and the company’s first, Coherus BioSciences’ management took to the J.P. Morgan Healthcare Conference to explain how the company is set apart from rival Mylan. Through debt financing, the California-based player has also just grabbed a further US$75 million to fuel the biosimilar’s launch.

Biosimilars Strategy

Mallinckrodt Details Timeline And Financing For Spinning Off Generics Business

Under plans announced last December, Mallinckrodt is to spin off its specialty generics and API business; at the recent Annual J.P. Morgan Healthcare Conference, management painted a timeline to completing the project and provided details on the business’ financing and growth prospects.

Strategy Deals
See All
Advertisement
UsernamePublicRestriction

Register